GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » PB Ratio

NanoVibronix (NanoVibronix) PB Ratio : 0.38 (As of May. 02, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), NanoVibronix's share price is $0.74. NanoVibronix's Book Value per Share for the quarter that ended in Dec. 2023 was $1.95. Hence, NanoVibronix's PB Ratio of today is 0.38.

The historical rank and industry rank for NanoVibronix's PB Ratio or its related term are showing as below:

NAOV' s PB Ratio Range Over the Past 10 Years
Min: 0.31   Med: 5.19   Max: 46.22
Current: 0.38

During the past 13 years, NanoVibronix's highest PB Ratio was 46.22. The lowest was 0.31. And the median was 5.19.

NAOV's PB Ratio is ranked better than
95.71% of 793 companies
in the Medical Devices & Instruments industry
Industry Median: 2.24 vs NAOV: 0.38

During the past 12 months, NanoVibronix's average Book Value Per Share Growth Rate was -1.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -4.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -10.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NanoVibronix was 51.30% per year. The lowest was -112.80% per year. And the median was -4.70% per year.

Back to Basics: PB Ratio


NanoVibronix PB Ratio Historical Data

The historical data trend for NanoVibronix's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix PB Ratio Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.91 6.79 4.61 2.56 0.59

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.59 4.89 0.77 0.59

Competitive Comparison of NanoVibronix's PB Ratio

For the Medical Devices subindustry, NanoVibronix's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's PB Ratio distribution charts can be found below:

* The bar in red indicates where NanoVibronix's PB Ratio falls into.



NanoVibronix PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

NanoVibronix's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.74/1.949
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


NanoVibronix  (NAS:NAOV) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


NanoVibronix PB Ratio Related Terms

Thank you for viewing the detailed overview of NanoVibronix's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022